Stephen M. Eulau, MD

Dr. Vicini and colleagues provide an excellent review of the experience to date utilizing interstitial brachytherapy in the treatment of locally advanced prostate cancer. As the authors mention, ample evidence suggests the existence of a dose-

Dr. Connors provides an excellent overview of several sites of extranodal lymphoma, which represent an unusual presentation of non-Hodgkin’s lymphoma. He outlines an organized, phased approach to diagnosis, staging, and treatment, emphasizing interdisciplinary management. In this review, we will add some perspectives from the Stanford experience.

Locally advanced adenocarcinoma of the prostate (American Urological Association stages B2, C; American Joint Committee on Cancer stages T2c, T3) has been difficult to control by either external-beam irradiation or